Trial Profile

OPV117059: A Long-Term Extension Study of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 26 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ofatumumab (Primary) ; Antihistamines; Paracetamol; Prednisolone
Indications Pemphigus vulgaris
Focus Adverse reactions
Sponsors GlaxoSmithKline; GSK

Most Recent Events

17 Jun 2016 Status changed from withdrawn prior to enrolment to discontinued.
12 May 2016 Status changed from discontinued to withdrawn prior to enrolment.
08 Mar 2016 According to Genmab media release, this study will be discontinued as company wants to focus on relapsing multiple sclerosis.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com